These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 38714665)

  • 1. Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer.
    Wang K; Zerdes I; Johansson HJ; Sarhan D; Sun Y; Kanellis DC; Sifakis EG; Mezheyeuski A; Liu X; Loman N; Hedenfalk I; Bergh J; Bartek J; Hatschek T; Lehtiö J; Matikas A; Foukakis T
    Nat Commun; 2024 May; 15(1):3837. PubMed ID: 38714665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome.
    Park YH; Lal S; Lee JE; Choi YL; Wen J; Ram S; Ding Y; Lee SH; Powell E; Lee SK; Yu JH; Ching KA; Nam JY; Kim SW; Nam SJ; Kim JY; Cho SY; Park S; Kim J; Hwang S; Kim YJ; Bonato V; Fernandez D; Deng S; Wang S; Shin H; Kang ES; Park WY; Rejto PA; Bienkowska J; Kan Z
    Nat Commun; 2020 Dec; 11(1):6175. PubMed ID: 33268821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer.
    Wilkins A; Fontana E; Nyamundanda G; Ragulan C; Patil Y; Mansfield D; Kingston J; Errington-Mais F; Bottomley D; von Loga K; Bye H; Carter P; Tinkler-Hundal E; Noshirwani A; Downs J; Dillon M; Demaria S; Sebag-Montefiore D; Harrington K; West N; Melcher A; Sadanandam A
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33678606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy.
    Waks AG; Stover DG; Guerriero JL; Dillon D; Barry WT; Gjini E; Hartl C; Lo W; Savoie J; Brock J; Wesolowski R; Li Z; Damicis A; Philips AV; Wu Y; Yang F; Sullivan A; Danaher P; Brauer HA; Osmani W; Lipschitz M; Hoadley KA; Goldberg M; Perou CM; Rodig S; Winer EP; Krop IE; Mittendorf EA; Tolaney SM
    Clin Cancer Res; 2019 Aug; 25(15):4644-4655. PubMed ID: 31061067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.
    Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D
    Front Immunol; 2021; 12():734646. PubMed ID: 34795663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-Cell Profiling to Explore Immunological Heterogeneity of Tumor Microenvironment in Breast Cancer.
    Yuan X; Wang J; Huang Y; Shangguan D; Zhang P
    Front Immunol; 2021; 12():643692. PubMed ID: 33717201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer.
    Wesolowski R; Stiff A; Quiroga D; McQuinn C; Li Z; Nitta H; Savardekar H; Benner B; Ramaswamy B; Lustberg M; Layman RM; Macrae E; Kassem M; Williams N; Sardesai S; VanDeusen J; Stover D; Cherian M; Mace TA; Yu L; Duggan M; Carson WE
    BMC Cancer; 2020 May; 20(1):445. PubMed ID: 32429929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy-Resistant Early Breast Cancers.
    Gazinska P; Milton C; Iacovacci J; Ward J; Buus R; Alaguthurai T; Graham R; Akarca A; Lips E; Naidoo K; Wesseling J; Marafioti T; Cheang M; Gillett C; Wu Y; Khan A; Melcher A; Salgado R; Dowsett M; Tutt A; Roxanis I; Haider S; Irshad S
    Clin Cancer Res; 2022 Oct; 28(20):4494-4508. PubMed ID: 36161312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.
    García-Martínez E; Gil GL; Benito AC; González-Billalabeitia E; Conesa MA; García García T; García-Garre E; Vicente V; Ayala de la Peña F
    Breast Cancer Res; 2014 Nov; 16(6):488. PubMed ID: 25432519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic and transcriptomic analysis of breast cancer identifies novel signatures associated with response to neoadjuvant chemotherapy.
    Yin G; Liu L; Yu T; Yu L; Feng M; Zhou C; Wang X; Teng G; Ma Z; Zhou W; Ye C; Zhang J; Ji C; Zhao L; Zhou P; Guo Y; Meng X; Fu Q; Zhang Q; Li L; Zhou F; Zheng C; Xiang Y; Guo M; Wang Y; Wang F; Huang S; Yu Z
    Genome Med; 2024 Jan; 16(1):11. PubMed ID: 38217005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune correlates of the differing pathological and therapeutic effects of neoadjuvant chemotherapy in breast cancer.
    Kim R; Kawai A; Wakisaka M; Sawada S; Shimoyama M; Yasuda N; Hidaka M; Morita Y; Ohtani S; Arihiro K
    Eur J Surg Oncol; 2020 Jan; 46(1):77-84. PubMed ID: 31563296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles of the Immune/Methylation/Autophagy Landscape on Single-Cell Genotypes and Stroke Risk in Breast Cancer Microenvironment.
    Wu JY; Qin J; Li L; Zhang KD; Chen YS; Li Y; Jin T; Xu JM
    Oxid Med Cell Longev; 2021; 2021():5633514. PubMed ID: 34457116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+ Early Stage Breast Cancer.
    Vanguri RS; Fenn KM; Kearney MR; Wang Q; Guo H; Marks DK; Chin C; Alcus CF; Thompson JB; Leu CS; Hibshoosh H; Kalinsky KM; Mathews JC; Nadeem S; Hollmann TJ; Connolly EP
    Clin Breast Cancer; 2022 Aug; 22(6):538-546. PubMed ID: 35610143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deletions of multidrug resistance gene loci in breast cancer leads to the down-regulation of its expression and predict tumor response to neoadjuvant chemotherapy.
    Litviakov NV; Cherdyntseva NV; Tsyganov MM; Slonimskaya EM; Ibragimova MK; Kazantseva PV; Kzhyshkowska J; Choinzonov EL
    Oncotarget; 2016 Feb; 7(7):7829-41. PubMed ID: 26799285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment.
    Azizi E; Carr AJ; Plitas G; Cornish AE; Konopacki C; Prabhakaran S; Nainys J; Wu K; Kiseliovas V; Setty M; Choi K; Fromme RM; Dao P; McKenney PT; Wasti RC; Kadaveru K; Mazutis L; Rudensky AY; Pe'er D
    Cell; 2018 Aug; 174(5):1293-1308.e36. PubMed ID: 29961579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Hamy AS; Bonsang-Kitzis H; De Croze D; Laas E; Darrigues L; Topciu L; Menet E; Vincent-Salomon A; Lerebours F; Pierga JY; Brain E; Feron JG; Benchimol G; Lam GT; Laé M; Reyal F
    Clin Cancer Res; 2019 Nov; 25(22):6731-6741. PubMed ID: 31515462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment.
    Al-Khanbashi M; Caramuta S; Alajmi AM; Al-Haddabi I; Al-Riyami M; Lui WO; Al-Moundhri MS
    PLoS One; 2016; 11(4):e0152032. PubMed ID: 27064979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation.
    Bauer JA; Chakravarthy AB; Rosenbluth JM; Mi D; Seeley EH; De Matos Granja-Ingram N; Olivares MG; Kelley MC; Mayer IA; Meszoely IM; Means-Powell JA; Johnson KN; Tsai CJ; Ayers GD; Sanders ME; Schneider RJ; Formenti SC; Caprioli RM; Pietenpol JA
    Clin Cancer Res; 2010 Jan; 16(2):681-90. PubMed ID: 20068102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel immune-related genes in the tumor microenvironment with prognostic value in breast cancer.
    Tan W; Liu M; Wang L; Guo Y; Wei C; Zhang S; Luo C; Liu N
    BMC Cancer; 2021 Feb; 21(1):126. PubMed ID: 33549054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next generation sequencing-based expression profiling identifies signatures from benign stromal proliferations that define stromal components of breast cancer.
    Guo X; Zhu SX; Brunner AL; van de Rijn M; West RB
    Breast Cancer Res; 2013 Dec; 15(6):R117. PubMed ID: 24342436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.